Evidence map›Paper›PMID 22496040›Full record

ArticlePediatric pulmonology2012

Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.

Robert Bradley Troxler, Wynton C Hoover, LaCrecia J Britton, Andrea M Gerwin, Steven M Rowe

Open access · greenAbstract read
In one paragraph

Article in Pediatric pulmonology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. How Three Self-Secreted Biofilm Exopolysaccharides ofInternational journal of molecular sciences · 2023
    Review
  2. Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019
    Article
  3. Review
  4. Review
  5. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Observational
  6. Review
  7. Highlights of the North American Cystic Fibrosis Conference 2009.Journal of the Royal Society of Medicine · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Robert Bradley TroxlerDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA. btroxler@peds.uab.edu
Wynton C Hoover
LaCrecia J Britton
Andrea M Gerwin
Steven M Rowe
University of Alabama at Birmingham · USChildren's of Alabama · USSamford University · USUniversity of Alabama at Birmingham Hospital · US

Funding

UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0M
Premature Termination Codon SuppressionK23DK075788 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROWE, STEVEN MARK · 2006 to 2010
$638k
Mechanistic Basis Underlying Protein Repair of CFTR Nonsense MutationsR03DK084110 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROWE, STEVEN MARK · 2009 to 2010
$146k
NIDDK NIH HHS 1R03DK084110-01NIDDK NIH HHS 5K23DK075788NIDDK NIH HHS K23 DK075788NIDDK NIH HHS P30 DK072482NIDDK NIH HHS R03 DK084110
6 · The paper itself

Abstract

backgroundAccelerated lung function decline in cystic fibrosis (CF) is associated with mucoid Pseudomonas aeruginosa infection. Recent data suggest that mucoid P. aeruginosa may amenable to elimination from the airway. We aim to determine whether the initiation of an aggressive antibiotic eradication regimen upon initial discovery of mucoid P. aeruginosa in the CF airway could be successful in clearing the organism from the CF lung.

methodsWe performed a retrospective analysis of patients with CF who demonstrated new growth of mucoid P. aeruginosa in an airway culture between January 2003 and December 2008. The primary endpoint was clearance of mucoid P. aeruginosa, based upon the Leeds criteria, with no further growth of mucoid P. aeruginosa cultures within 12 months of the initial discovery and treatment. Factors associated with successful clearance were also evaluated.

resultsForty-eight of 355 patients with CF had a new diagnosis of mucoid P. aeruginosa during the study period; 15 patients underwent an eradication attempt, while 33 patients received no increase in therapy. We observed clearance of mucoid P. aeruginosa in 73.3% of patients undergoing an eradication attempt, whereas 36.6% of those that did not undergo attempted eradication cleared the organism at 1 year (P < 0.05). Prolonged mucoid P. aeruginosa airway clearance (>24 months) for mucoid P. aeruginosa was seen in 60.0% in subjects undergoing eradication compared to 21.2% (P = 0.02) in control patients. At the study conclusion, lung function was greater in subjects who underwent an eradication attempt than in patients who did not undergo an eradication attempt (FEV(1) %: 91.7% vs. 75.0%, P = 0.04).

conclusionsClearance of initial mucoid P. aeruginosa from the airways of select patients with CF is possible with current antibiotic regimens, and the attempt may be associated with improved lung function.

Indexed as

Anti-Bacterial AgentsChildChild, PreschoolCystic FibrosisFemaleHumansLungMalePseudomonas aeruginosaPseudomonas InfectionsRecurrenceRespiratory Function TestsRetrospective StudiesAnti-Bacterial Agents

Identifiers

PMID22496040
PMCPMC3707148
OpenAlexW2016282816

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.